(Q24244310)

10

0 references

Saskia Middeldorp

7

0 references

Heather O. Dickinson

9

0 references

Elie A Akl

1

0 references

Victor E D Yosuico

8

object named as

Victor E D Yosuico

0 references

Frederiek F van Doormaal

2

object named as

Frederiek F van Doormaal

0 references

author name string

Ganesh Kamath

4

0 references

Seo Young Kim

5

0 references

Saskia Kuipers

Cochrane Database of Systematic Reviews

6

0 references

publication date

18 July 2007

0 references

published in

0 references

cites work

Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

Low molecular weight heparins could be important in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

Heparin and chemotherapy in the management of inoperable lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Increasing the efficiency of cancer chemotherapy with heparin: "clinical study".

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Heparin treatment of malignancy: the case for clinical trials in colon cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Low dose intravesical heparin as prophylaxis against recurrent noninvasive (stage Ta) bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Heparin and cancer revisited

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Can low-molecular-weight heparins improve outcome in patients with cancer?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Do low-molecular-weight heparins improve the survival of cancer patients?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Heparin-induced thrombocytopenia: a review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Hemostasis and malignancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Antidepressants for old people. Research on antidepressants in the elderly population is scarce

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Heparin for colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

The effect of low molecular weight heparin on survival in patients with advanced malignancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Can low-molecular-weight heparin improve the outcome of patients with operable non-small cell lung cancer? An urgent call for research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021

Low-molecular-weight heparin and outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652

7 January 2021